SRD5A2 was previously identified in a candidate screen of 732 PCa-related genes [22] and forms part of the commercial Oncotype DX Genomic Prostate Score assay that predicts tumour aggressiveness in low and intermediate risk PCa. Here, SRD5A2 is linked to neoplasm.